In this conversation, Global Liver Institute Founder, President, and CEO Donna Cryer describes the history of the basic Patient-Focussed Drug Development concept and this particular Fatty Liver event. Patient and patient advocate Terri Milton discusses the message she hoped regulators would take away from this session and why she believes the group may have succeeded. Finally, the group discusses why regulators and advocates vary so greatly in terms of how they view the efficacy: safety tradeoff for first-in-class drugs.
